Distinct scleroderma autoantibody profiles stratify patients for cancer risk at scleroderma onset and during the disease course.

These data suggest that 5 distinct scleroderma immune responses, alone or in combination, may be useful tools to stratify scleroderma patients' cancer risk. Further study examining cancer risk in autoantibody subgroups relative to the general population is warranted.